The identification and further characterization of these clients of the HSP70/BAG1 complex provides the initial step towards targeted therapies that can convert MYC from a pro-tumorigenic oncogene to a pro-apoptotic tumor suppressor. The gene discussed is BAG1; the disease is neoplasm.